Lipodystrophy - A sign for metabolic syndrome in patients of the HIV-HEART study;Lipodystrophie als Hinweis für das metabolische Syndrom bei Patienten der HIV-HEART-Studie

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue 2, 2010, Pages 92-98

  Potthoff, Anja ^a   Brockmeyer, Norbert H ^a   Gelbrich, Götz ^b   Neuhaus, Kathrin ^c   Esser, Stefan ^c   Reinsch, Nico ^c   Hower, Martin ^d   Mostardt, Sarah ^c   Neumann, Anja ^c   Neumann, Till ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d KLINIKUM DORTMUND   (Germany)

Author keywords

AIDS; HIV; Lipodystrophy; Metabolic syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; QUALITY OF LIFE; SEX DIFFERENCE; SHORT FORM 36;

EID: 76149115901     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07330_supp.x     Document Type: Article

References (28)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD EuroSIDA Study Group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003 362 : 22 9.
2. Bechara FG, Sand M, Potthoff A, Altmeyer P, Brockmeyer NH German Competence Network for HIV/AIDS. HIV-associated lipodystrophy - review of current therapy options. Eur J Med Res 2008 13 : 1 7.
3. Koutkia P, Grinspoon S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu Rev Med 2004 55 : 303 317.
4. Ho JE, A, Priscilla YH. Cardiovascular manifestations of HIV infection. Heart 2009 95 : 1193 1202.
5. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J, Cooper DA Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004 18 : 1029 1036.
6. Hansen BR, Petersen J, Haugaard SB, Madsbad S, Obel N, Suzuki Y, Andersen O. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med 2009 10 : 378 387.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 2497.
8. European AIDS Clinical Society (EACS). Guidelines on the Prevention and Management of Metabolic diseases in HIV. English version 4 October 2008 http://www.europeanaidsclinicalsociety.org/guidelinespdf/2-Prevention-and- Management-of-Metabolic-diseases-in-HIV.pdf
9. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, doubleblind, placebo-controlled trial. Lancet 2004 363 : 429 438.
10. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M, Yki-Jarvinen H. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther 2003 8 : 199 207.
11. van Wijk JP, de Koning EJ, Cabezas MC, op't Roodt J, Joven J, Rabelink TJ, Hoepelman AI. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005 143 : 337 346.
12. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000 284 : 472 477.
13. Neumann T, Esser S, Potthoff A, Neumann A, Breukmann F, Neuhaus K, Kondratieva J, Buck T, Müller-Tasch T, Wachter R, Prettin C, Gelbrich G, Herzog W, Pieske B, Rauchhaus M, Löffler M, Maisch B, Mügge A, Wasem J, Gerke G, Brockmeyer NH, Erbel R. HIV-HEART Study Investigative Group. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res 2007 12 : 243 248.
14. Lamping DL. Messung der Lebensqualität bei HIV-Infektionen: Validierung des SF-36 Short-Form Health Survey. Int Conf AIDS 1993 Jun 6-11; 9: 780 (abstract no. PO-C35-3377).
15. http://www.sf-36.org/
16. Zannou DM, Denoeud L, Lacombe K, Amoussou-Guenou D, Bashi J, Akakpo J, Gougounon A, Akondé A, Adé G, Houngbé F, Girard PM. Incidence of lipodystrophy and metaoblic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Anti-vir Ther 2009 14 : 371 380.
17. Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Aven R, Grassi J, Clotet B. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother 2009 53 : 1937 1943.
18. de Mendoza C, Soriano V. The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals Antivir Ther 2005 10 (Suppl 2 M109 15.
19. Heyman WR. Lipodystrophies and the metabolic syndrome. J Am Acad Dermatol 2008 59 : 87 8.
20. Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol 2009 21 : 132 137.
21. Chobanian AV, Bakris GL, Black HR, Cusman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Rocella EJ and the National High Blood Pressure education program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003 42 : 1206 1252. (Pubitemid 37553153)
22. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Gastagliola D, Jougla E, Semaille C, Merlat P, Salmon D, Cacoub P, Chêne G ANRS EN 19 Mortalité Sty Group and Motavic 1. Changes in Causes of Death Among Adults Infected by HIV Between and 2005: The "Mortalité 2000 and 2005" Surveys (ANRS EN 19 and Mortavic). J Acquir Immune Defic Syndr 2008 48 : 590 598.
23. Nisoli E, Clementi E, Carruba MO, Moncada S. Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 2007 100 : 795 806.
24. Samara K, Gan SK, Peake PW, Carr A, Campbell LV. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity 2009 17 : 53 9.
25. Bugger H, Abel ED. Molekular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Cli Sci 2008 114 : 195 210.
26. Joy T, Keogh HM, Hadigan C, Dolan SE, Fitch K, Liebau J, Johnsen S, Lo J, Grinspoon SK. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr 2008 47 : 174 184.
27. Brown TT, Xu X, John M, AmoussouGuenou D, Bashi J, Akakpo J, Gougounon A, Akondé A, Adé G, Houngbé F, Girard PM. Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study. AIDS Res Ther 2009 6 : 8.
28. Esch P. Caring for HIV-positive and aging patients with associated facial lipoatrophy. Plastic Surgical Nursing 2006 26 : 17 23.